322 results
8-K
EX-4.2
SEEL
Seelos Therapeutics Inc
21 May 24
Entry into a Material Definitive Agreement
4:01pm
be entitled to the benefits of the provisions of this Section 3(d) regardless of (i) whether the Company has sufficient authorized shares of Common Stock
8-K
EX-10.1
SEEL
Seelos Therapeutics Inc
21 May 24
Entry into a Material Definitive Agreement
4:01pm
benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for the purpose … ) reimbursement for expenses incurred on behalf of the Company and (iii) other employee benefits, including stock option agreements, restricted stock
8-K
EX-4.1
SEEL
Seelos Therapeutics Inc
21 May 24
Entry into a Material Definitive Agreement
4:01pm
and severally, had been named as the Company herein. For the avoidance of doubt, the Holder shall be entitled to the benefits of the provisions of this Section 3
8-K
EX-10.2
SEEL
Seelos Therapeutics Inc
21 May 24
Entry into a Material Definitive Agreement
4:01pm
to the Liabilities and Expenses paid or payable by such Indemnified Person in such proportion as is appropriate to reflect (i) the relative benefits to the Company … or (ii) if the allocation provided by the immediately preceding clause is not permitted by applicable law, not only such relative benefits but also
424B5
SEEL
Seelos Therapeutics Inc
20 May 24
Prospectus supplement for primary offering
4:16pm
approximately $50,000 in total charges for related benefits for employees whose employment was terminated pursuant to the RIF. These are one-time termination … benefits and are cash charges. The estimates of costs and expenses that we expect to incur in connection with the RIF are subject to a number
8-K
wb3do2 h223eplm3q
3 May 24
Entry into a Material Definitive Agreement
5:06pm
424B3
xih142qu
15 Mar 24
Prospectus supplement
4:15pm
8-K
EX-10.1
fm6thc4
30 Jan 24
Entry into a Material Definitive Agreement
4:01pm
8-K
EX-4.1
vsoxz0 d66zdwkxtod0
30 Jan 24
Entry into a Material Definitive Agreement
4:01pm
8-K
EX-10.2
u4eetnsg0nfz8pb
30 Jan 24
Entry into a Material Definitive Agreement
4:01pm
8-K
EX-1.1
w2b8hs1tk5n6pj 42
30 Nov 23
Seelos Therapeutics Announces Pricing of $5.55 Million Public Offering
4:59pm
8-K
EX-4.1
gwm7ulj
30 Nov 23
Seelos Therapeutics Announces Pricing of $5.55 Million Public Offering
4:59pm